Nucala Dosage/Direction for Use

NUCALA should be prescribed by a specialist experienced in the diagnosis and treatment of severe eosinophilic asthma.
NUCALA should be reconstituted and administered by a health care professional.
Following reconstitution, NUCALA should only be administered as a subcutaneous injection (e.g. upper arm, thigh, or abdomen) (see Instructions for Use/Handling under Cautions for Usage).
Posology: Severe Eosinophilic Asthma: Adults and Adolescents (12 years and older): The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
The safety and efficacy of NUCALA have not been established in adolescents weighing less than 45kg.
NUCALA is intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient's disease severity and level of control of exacerbations.
Children (up to 12 years of age): The safety and efficacy of NUCALA have not been established in children less than 12 years of age.
Elderly (65 years or older): No dosage adjustment is recommended in patients 65 years or older (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).
Renal Impairment: Dose adjustments in patients with renal impairment are unlikely to be required (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).
Hepatic Impairment: Dose adjustments in patients with hepatic impairment are unlikely to be required (see Pharmacology: Pharmacokinetics: Special Patient Populations under Actions).